Alphabetical list:
A B C D E F G H I J K L M N O P R S T U V W X Y Q Z 1 2 3 4 5 6 7 8 9
News: November 29, 2009
Rituximab May Offer Hope To Severe Graves' Eye Disease Patients
November 29, 2009There may be hope for patients with severe Graves' eye disease in the form of treatment with the drug rituximab.
This news comes from U-M Kellogg Eye Center who's oculoplastics specialist Raymond S. Douglas, M.D., Ph.D. reports on the potential of the drug in the online October issue of Ophthalmology.
Graves' eye disease is an autoimmune disease that causes inflammation and fatty deposits in the eye muscles and connective tissue surrounding the eye.
Douglas reports on the progress of six patients (four women, two men) who had not responded to treatment using systemic corticosteroids. The patients were then treated with rituximab. All patients responded within 2 months with the clinical activity score (CAS) improving from5.5±0.8 to 1.3±0.5. The eye disease remained quiescent in all with the positive results being sustained at 4-6 months after treatment.
Vision improved bilaterally in all 4 patients with dysthyroid optic neuropathy (DON). Proptosis remained stable (Hertel measurement, 24±3.7 mm before therapy and 23.6±3.7 mm after therapy; P = 0.17).
"These patients had already received the maximum level of steroid treatment," says Douglas. "Treatment with rituximab calmed inflammation, stopped progression of the disease, and saved the patients from having to undergo surgery."
Graves' disease (also known as thyroid eye disease) is an autoimmune condition in which white blood cells attack the thyroid gland which responds by secreting an excess amount of thyroid hormone. The hypermetabolic state is characterized by fast pulse/heartbeat, palpitations, profuse sweating, high blood pressure, irritability, fatigue, weight loss, heat intolerance, and loss of hair and alterations in hair quality.
Rituximab has been used to treat patients with other autoimmune diseases, including rheumatoid arthritis and in non-Hodgkin's B-cell lymphoma. The drug works by depleting B cells - the body's normal antibody-producing cells - that appear to go awry in autoimmune diseases.
"Treatment of the inflammatory component of Graves' eye disease has not advanced appreciably over several decades," says Douglas. High-dose steroids, sometimes in combination with orbital radiation, are still the first line treatment. But, says Douglas, "These are imperfect options because inflammation often recurs when the treatment ends." He is hopeful that rituximab can offer sustained improvement. Douglas observes that the results from a small case series must be viewed with some caution. But given the substantial benefits for patients treated with rituximab, he sees good reason to proceed with a large-scale clinical trial to test this promising new drug.
Source
Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy; Ophthalmology, 2009; Chong et al.; DOI: 10.1016/j.ophtha.2009.05.029
University of Michigan Health System Newsroom
Archive issues: (50)
Archive list: 1 2 3 [4] 5 6 7 8 9 10 11 12 13 14 15 16 17
December 5, 2009 | Half of teen girls have STIs by 2 years of first sexWithin 2 years of having sex for the first time, half of teenage girls may be at least one of three common sexually transmitted infections (STIs), according to results of a study published today. Often, those girls are infected by the age ...
December 4, 2009 | Antidepressants May Change Your PersonalityTaking antidepressants may not only help alleviate depression, but could make you more extraverted and less neurotic, new research suggests. Extraversion, which is associated with positive emotions, is believed to help protect from depression, while ...
December 3, 2009 | Smoking Exposure Now Linked to Colon, Breast CancersAdd colorectal cancer to the list of malignancies caused by smoking, with a new study strengthening the link between the two. And other studies are providing more bad news for people who haven't managed to quit: Two papers published in the December issue of Epidemiology, Biomarkers & Prevention, a themed issue on tobacco, strengthen the case for ...
Related articles:
Chronic bacterial prostatitis - treatment
Treatment requires prolonged courses (4-8 weeks) of antibiotics that penetrate the prostate well (?-lactams and nitrofurantoin are ineffective). These include quinolones (ciprofloxacin, levofloxacin), sulfas (Bactrim, Septra) and macrolides (erythromycin, clarithromycin). Persistent infections may be helped in 80% of patients by the use of alpha blockers (tamsulosin (Flomax), alfuzosin), or ...Section: Prostatitis
Treatment - medication (bladder instillations)
DMSO, a wood pulp extract, is the only approved bladder instillation for IC/PBS yet it is much less frequently used in urology clinics. Research studies presented at recent conferences of the American Urological Association by C. Subah Packer have demonstrated that the FDA approved dosage of a 50% solution of DMSO had the potential of creating irreversible muscle contraction. However, a lesser solution of 25% was found to be reversible. Long term use is ...Section: Interstitial cystitis